Qiming Venture Partners and Portfolio Companies Win 2026 Golden Eagle Venture Capital and Sci-Tech Innovation Seedling Awards

Securities Times recently released its 2026 Venture Capital Golden Eagle Awards and 2026 Sci-Tech Innovation Seedling Awards. Qiming Venture Partners was named VC Firm of the Year, Exit Firm of the Year, Excellence in AI Investment, and Excellence in Healthcare Investment. Alex Zhou, Managing Partner at Qiming Venture Partners, received the 2026 Venture Capital Golden Eagle Investor of the Year award. Two Qiming portfolio companies, Cix Technology and Belief BioMed, were recognized as Innovative Pioneer Enterprises of the Year. Qiming Venture Partners — VC Firm of the Year, Exit Firm of the Year, Excellence in AI Investment, Excellence in Healthcare Investment Alex Zhou, Managing Partner — Investor of the Year Cix Technology and Belief BioMed — Innovative Pioneer Enterprises of the Year Since 2009, Securities Times has kept a steady focus on the venture capital industry's evolution, consistently identifying outstanding leaders in the field while witnessing startups grow from tender seedlings into towering trees. In this year's competition, Alex Zhou was invited to serve as an expert judge for the Startup Seedling Awards. Following more than two months of applications, voting, and evaluation — with over 400 institutions and companies competing — a select group of resilient and dynamic VC firms and startups emerged as winners.

Past Highlights

Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol. 25, August 11, 2026 Qiming Headlines | WAIC Qiming Venture Partners · Entrepreneurship and Investment Forum — From Compute Origin to Application Deployment Successfully Held Qiming Stars | Highlight Moments! WAIC 2026 Qiming Venture Partners and Portfolio Companies Win Major Awards

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.

Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), HEC Pharma, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.